Therefore, most of the advanced AD drugs act on Th2 immunity, including the Il-4r antagonist Dupilumab, the biologic agent Dupixent targeting Il-4/13, the biologic agent Lebrikizumab targeting Il-13, and the humanized monoclonal anti-IL-31Rα antibody Nemolizumab (53). Here, IL13 is linked to Alzheimer disease.